3 Healthcare Stock Stories For a Thursday Investment Checkup

Sanofi-Aventis (NYSE:SNY): Closing price $51.05

This week, Chinese authorities paid a visit to a Shenyang regional office of the French drug maker Sanofi in the most recent indication of a growing inquiry into Western drug companies. Eli Lilly reported that it had also been visited by officials in the same city of Shenyang, as part of a “routine” investigation which had begun earlier this year, while the CEO of AstraZenec, which has a sales executive detained in Shanghai, warned of short-term “turmoil” in the sector. These latest developments imply a series of inquiries into over-pricing and claims of bribery in the industry which could have a broad impact in a market that has been a refuge for Western pharmaceuticals who face slumping sales at home.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY-20130801

AstraZeneca (NYSE:AZN): Closing price $50.81

AstraZeneca is growing its investment in China, in which sales jumped by 21 percent in the second quarter, as that country continues its crackdown on alleged malfeasance in the healthcare industry. The United Kingdom’s number-two drug manufacturer has hired additional sales people in China as medical coverage there expands, even though prices have declined, AstraZeneca Chief Executive Pascal Soriot told journalists Wednesday in a conference call regarding earnings. He commented that “Our organization in China is very focused on doing business in China the right way. Our focus is on science and developing medicines that help patients. There are 1.2 billion patients in China, so we are very focused on growing in China.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AZN-20130801

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): Closing price $39.42

While the generic drug firm Teva reported a second-quarter loss as it reserved $1.4 billion to cover costs linked with a patent suit, the firm announced a $1.6-billion settlement of a patent infringement lawsuit concerning the heartburn drug Protonix. Teva had already set aside $670 million to cover a potential resolution, and put aside an additional $930 million in the second quarter to cover the remainder. The company also put $485 million in reserve for antitrust litigation over the sleep disorder medicine Provigil, and it took $288 million in amortization costs connected with acquisitions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TEVA-20130801

Don’t Miss: 5 Reasons Why Obamacare Is Proving to be so Complex.